{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,20]],"date-time":"2026-01-20T17:31:29Z","timestamp":1768930289136,"version":"3.49.0"},"reference-count":35,"publisher":"The Endocrine Society","issue":"7","license":[{"start":{"date-parts":[[2021,3,8]],"date-time":"2021-03-08T00:00:00Z","timestamp":1615161600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"New Investigator Award","award":["102820\/Z\/13\/Z"],"award-info":[{"award-number":["102820\/Z\/13\/Z"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2021,6,16]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>Aims\/Hypothesis<\/jats:title><jats:p>Studies in permanent neonatal diabetes suggest that sulphonylureas lower blood glucose without causing hypoglycemia, in part by augmenting the incretin effect. This mechanism has not previously been attributed to sulphonylureas in patients with type 2 diabetes (T2DM). We therefore aimed to evaluate the impact of low-dose gliclazide on beta-cell function and incretin action in patients with T2DM.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>Paired oral glucose tolerance tests and isoglycemic infusions were performed to evaluate the difference in the classical incretin effect in the presence and absence of low-dose gliclazide in 16 subjects with T2DM (hemoglobin A1c\u2005&amp;lt;\u200564 mmol\/mol, 8.0%) treated with diet or metformin monotherapy. Beta-cell function modeling was undertaken to describe the relationship between insulin secretion and glucose concentration.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>A single dose of 20 mg gliclazide reduced mean glucose during the oral glucose tolerance test from 12.01\u2005\u00b1\u20050.56 to 10.82\u2005\u00b1\u20050.5mmol\/l [P\u2005=\u20050.0006; mean\u2005\u00b1\u2005standard error of the mean (SEM)]. The classical incretin effect was augmented by 20 mg gliclazide, from 35.5% (lower quartile 27.3, upper quartile 61.2) to 54.99% (34.8, 72.8; P\u2005=\u20050.049). Gliclazide increased beta-cell glucose sensitivity by 46% [control 22.61\u2005\u00b1\u20053.94, gliclazide 33.11\u2005\u00b1\u20057.83 (P\u2005=\u20050.01)] as well as late-phase incretin potentiation [control 0.92\u2005\u00b1\u20050.05, gliclazide 1.285\u2005\u00b1\u20050.14 (P\u2005=\u20050.038)].<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions\/Interpretation<\/jats:title><jats:p>Low-dose gliclazide reduces plasma glucose in response to oral glucose load, with concomitant augmentation of the classical incretin effect. Beta-cell modeling shows that low plasma concentrations of gliclazide potentiate late-phase insulin secretion and increase glucose sensitivity by 50%. Further studies are merited to explore whether low-dose gliclazide, by enhancing incretin action, could effectively lower blood glucose without risk of hypoglycemia.<\/jats:p><\/jats:sec>","DOI":"10.1210\/clinem\/dgab151","type":"journal-article","created":{"date-parts":[[2021,3,11]],"date-time":"2021-03-11T07:15:02Z","timestamp":1615446902000},"page":"2036-2046","source":"Crossref","is-referenced-by-count":19,"title":["The Impact of Low-dose Gliclazide on the Incretin Effect and Indices of Beta-cell Function"],"prefix":"10.1210","volume":"106","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3022-2451","authenticated-orcid":false,"given":"Ruth L M","family":"Cordiner","sequence":"first","affiliation":[{"name":"Division of Population Health and Genomics, School of Medicine, University of Dundee, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andrea","family":"Mari","sequence":"additional","affiliation":[{"name":"Institute of Neuroscience, National Research Council, Padua, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andrea","family":"Tura","sequence":"additional","affiliation":[{"name":"Institute of Neuroscience, National Research Council, Padua, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9237-8585","authenticated-orcid":false,"given":"Ewan R","family":"Pearson","sequence":"additional","affiliation":[{"name":"Division of Population Health and Genomics, School of Medicine, University of Dundee, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"80","published-online":{"date-parts":[[2021,3,8]]},"reference":[{"issue":"1","key":"2021122203513109000_CIT0001","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1007\/BF02427280","article-title":"Reduced incretin effect in type 2 (non-insulin-dependent) diabetes","volume":"29","author":"Nauck","year":"1986","journal-title":"Diabetologia"},{"key":"2021122203513109000_CIT0002","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1016\/j.metabol.2019.04.014","article-title":"The incretin system in healthy humans: The role of GIP and GLP-1","volume":"96","author":"Holst","year":"2019","journal-title":"Metabolism"},{"key":"2021122203513109000_CIT0003","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1111\/dom.13129","article-title":"Incretin hormones: their role in health and disease","volume":"20","author":"Nauck","year":"2018","journal-title":"Diabetes Obes Metab"},{"issue":"5","key":"2021122203513109000_CIT0004","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1007\/s00125-009-1314-y","article-title":"Regulation of insulin secretion: a matter of phase control and amplitude modulation","volume":"52","author":"Henquin","year":"2009","journal-title":"Diabetologia"},{"issue":"9","key":"2021122203513109000_CIT0005","doi-asserted-by":"crossref","first-page":"1412","DOI":"10.2337\/diabetes.47.9.1412","article-title":"Tissue specificity of sulfonylureas: studies on cloned cardiac and beta-cell K(ATP) channels","volume":"47","author":"Gribble","year":"1998","journal-title":"Diabetes"},{"issue":"1-2","key":"2021122203513109000_CIT0006","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1016\/j.mce.2008.08.012","article-title":"The incretin system and its role in type 2 diabetes mellitus","volume":"297","author":"Holst","year":"2009","journal-title":"Mol Cell Endocrinol"},{"issue":"3","key":"2021122203513109000_CIT0007","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1046\/j.1464-5491.2001.00449.x","article-title":"Association studies of variants in promoter and coding regions of beta-cell ATP-sensitive K-channel genes SUR1 and Kir6.2 with type 2 diabetes mellitus (UKPDS 53)","volume":"18","author":"Gloyn","year":"2001","journal-title":"Diabet Med"},{"issue":"18","key":"2021122203513109000_CIT0008","doi-asserted-by":"crossref","first-page":"1838","DOI":"10.1056\/NEJMoa032922","article-title":"Activating mutations in the gene encoding the ATP-sensitive potassium-channel subunit Kir6.2 and permanent neonatal diabetes","volume":"350","author":"Gloyn","year":"2004","journal-title":"N Engl J Med"},{"issue":"9","key":"2021122203513109000_CIT0009","doi-asserted-by":"crossref","first-page":"2503","DOI":"10.2337\/diabetes.54.9.2503","article-title":"Activating mutations in Kir6.2 and neonatal diabetes: new clinical syndromes, new scientific insights, and new therapy","volume":"54","author":"Hattersley","year":"2005","journal-title":"Diabetes"},{"issue":"9","key":"2021122203513109000_CIT0010","doi-asserted-by":"crossref","first-page":"1989","DOI":"10.2337\/db20-0074","article-title":"GIP and GLP-1 potentiate sulfonylurea-induced insulin secretion in hepatocyte nuclear factor 1\u03b1 Mutation carriers","volume":"69","author":"Christensen","year":"2020","journal-title":"Diabetes"},{"issue":"5","key":"2021122203513109000_CIT0011","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1056\/NEJMoa061759","article-title":"Switching from insulin to oral sulfonylureas in patients with diabetes due to Kir6.2 mutations","volume":"355","author":"Pearson","year":"2006","journal-title":"N Engl J Med"},{"issue":"2","key":"2021122203513109000_CIT0012","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1002\/cpt.1484","article-title":"Diabetes: is there a future for pharmacogenomics guided treatment?","volume":"106","author":"Pearson","year":"2019","journal-title":"Clin Pharmacol Ther"},{"issue":"1","key":"2021122203513109000_CIT0013","doi-asserted-by":"crossref","first-page":"16","DOI":"10.2337\/diab.44.1.16","article-title":"Reduction of the incretin effect in rats by the glucagon-like peptide 1 receptor antagonist exendin (9-39) amide","volume":"44","author":"Kolligs","year":"1995","journal-title":"Diabetes"},{"key":"2021122203513109000_CIT0014","article-title":"The incretin effect, how to measure it?","author":"Knop"},{"issue":"2","key":"2021122203513109000_CIT0015","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1210\/jcem-63-2-492","article-title":"Incretin effects of increasing glucose loads in man calculated from venous insulin and C-peptide responses","volume":"63","author":"Nauck","year":"1986","journal-title":"J Clin Endocrinol Metab"},{"issue":"6","key":"2021122203513109000_CIT0016","doi-asserted-by":"crossref","first-page":"1199","DOI":"10.1007\/s00125-014-3219-7","article-title":"Altered pattern of the incretin effect as assessed by modelling in individuals with glucose tolerance ranging from normal to diabetic","volume":"57","author":"Tura","year":"2014","journal-title":"Diabetologia"},{"key":"2021122203513109000_CIT0017","doi-asserted-by":"crossref","first-page":"S221","DOI":"10.2337\/diabetes.51.2007.S221","article-title":"Assessing insulin secretion by modeling in multiple-meal tests: role of potentiation","volume":"51","author":"Mari","year":"2002","journal-title":"Diabetes"},{"issue":"2","key":"2021122203513109000_CIT0018","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1210\/jc.2008-1731","article-title":"KATP channel closure ameliorates the impaired insulinotropic effect of glucose-dependent insulinotropic polypeptide in patients with type 2 diabetes","volume":"94","author":"Aaboe","year":"2009","journal-title":"J Clin Endocrinol Metab"},{"issue":"6","key":"2021122203513109000_CIT0019","doi-asserted-by":"crossref","first-page":"E1159","DOI":"10.1152\/ajpendo.00093.2002","article-title":"Meal and oral glucose tests for assessment of beta-cell function: modeling analysis in normal subjects","volume":"283","author":"Mari","year":"2002","journal-title":"Am J Physiol Endocrinol Metab"},{"key":"2021122203513109000_CIT0020","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1111\/j.1463-1326.2008.00946.x","article-title":"Beta-cell function assessment from modelling of oral tests: an effective approach","volume":"10 Suppl 4","author":"Mari","year":"2008","journal-title":"Diabetes Obes Metab"},{"issue":"9","key":"2021122203513109000_CIT0021","doi-asserted-by":"crossref","first-page":"e73154","DOI":"10.1371\/journal.pone.0073154","article-title":"Mechanisms of the incretin effect in subjects with normal glucose tolerance and patients with type 2 diabetes","volume":"8","author":"Mari","year":"2013","journal-title":"PloS One"},{"issue":"9392","key":"2021122203513109000_CIT0022","doi-asserted-by":"crossref","first-page":"1275","DOI":"10.1016\/S0140-6736(03)14571-0","article-title":"Genetic cause of hyperglycaemia and response to treatment in diabetes","volume":"362","author":"Pearson","year":"2003","journal-title":"Lancet"},{"issue":"4","key":"2021122203513109000_CIT0023","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1507\/endocrj.51.393","article-title":"Efficacy and safety of once daily gliclazide (20 mg\/day) compared with nateglinide","volume":"51","author":"Miwa","year":"2004","journal-title":"Endocr J"},{"issue":"2","key":"2021122203513109000_CIT0024","doi-asserted-by":"crossref","first-page":"438","DOI":"10.2337\/db06-0738","article-title":"Sulfonylurea compounds uncouple the glucose dependence of the insulinotropic effect of glucagon-like peptide 1","volume":"56","author":"de Heer","year":"2007","journal-title":"Diabetes"},{"issue":"1","key":"2021122203513109000_CIT0025","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1152\/physrev.00008.2017","article-title":"Pancreatic \u03b2-cell electrical activity and insulin secretion: of mice and men","volume":"98","author":"Rorsman","year":"2018","journal-title":"Physiol Rev"},{"issue":"3","key":"2021122203513109000_CIT0026","doi-asserted-by":"crossref","first-page":"496","DOI":"10.2337\/db17-1039","article-title":"Defective amplifying pathway of \u03b2-cell secretory response to glucose in type 2 diabetes: integrated modeling of in vitro and in vivo evidence","volume":"67","author":"Grespan","year":"2018","journal-title":"Diabetes"},{"issue":"12","key":"2021122203513109000_CIT0027","doi-asserted-by":"crossref","first-page":"4702","DOI":"10.1210\/jc.2013-1199","article-title":"Improved glycemic control enhances the incretin effect in patients with type 2 diabetes","volume":"98","author":"An","year":"2013","journal-title":"J Clin Endocrinol Metab"},{"issue":"11","key":"2021122203513109000_CIT0028","doi-asserted-by":"crossref","first-page":"1268","DOI":"10.1111\/j.1464-5491.2008.02579.x","article-title":"Four weeks of near-normalization of blood glucose has no effect on postprandial GLP-1 and GIP secretion, but augments pancreatic B-cell responsiveness to a meal in patients with type 2 diabetes","volume":"25","author":"H\u00f8jberg","year":"2008","journal-title":"Diabet Med"},{"key":"2021122203513109000_CIT0029","first-page":"375134","article-title":"Bioequivalence study of modified-release gliclazide tablets in healthy volunteers","volume":"2012","author":"Rojanasthien","year":"2012","journal-title":"ISRN Pharmacol"},{"issue":"9","key":"2021122203513109000_CIT0030","doi-asserted-by":"crossref","first-page":"1357","DOI":"10.2165\/00003495-200262090-00010","article-title":"Gliclazide modified release","volume":"62","author":"McGavin","year":"2002","journal-title":"Drugs"},{"issue":"3","key":"2021122203513109000_CIT0031","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1016\/j.diabres.2005.04.002","article-title":"Secondary sulfonylurea failure: comparison of period until insulin treatment between diabetic patients treated with gliclazide and glibenclamide","volume":"70","author":"Satoh","year":"2005","journal-title":"Diabetes Res Clin Pract"},{"issue":"8","key":"2021122203513109000_CIT0032","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1111\/j.1365-2362.2004.01381.x","article-title":"GUIDE study: double-blind comparison of once-daily gliclazide MR and glimepiride in type 2 diabetic patients","volume":"34","author":"Schernthaner","year":"2004","journal-title":"Eur J Clin Invest"},{"key":"2021122203513109000_CIT0033","year":"2015"},{"issue":"4","key":"2021122203513109000_CIT0034","doi-asserted-by":"crossref","first-page":"713","DOI":"10.1111\/jdi.12807","article-title":"Effectiveness and acceptability of continuous glucose monitoring for type 2 diabetes management: a narrative review","volume":"9","author":"Taylor","year":"2018","journal-title":"J Diabetes Investig"},{"issue":"8","key":"2021122203513109000_CIT0035","doi-asserted-by":"crossref","first-page":"1951","DOI":"10.2337\/db07-0100","article-title":"Reduced incretin effect in type 2 diabetes: cause or consequence of the diabetic state?","volume":"56","author":"Knop","year":"2007","journal-title":"Diabetes"}],"container-title":["The Journal of Clinical Endocrinology &amp; Metabolism"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/jcem\/advance-article-pdf\/doi\/10.1210\/clinem\/dgab151\/38196864\/dgab151.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jcem\/article-pdf\/106\/7\/2036\/41848720\/dgab151.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jcem\/article-pdf\/106\/7\/2036\/41848720\/dgab151.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,22]],"date-time":"2023-10-22T22:55:39Z","timestamp":1698015339000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jcem\/article\/106\/7\/2036\/6162832"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,3,8]]},"references-count":35,"journal-issue":{"issue":"7","published-online":{"date-parts":[[2021,3,8]]},"published-print":{"date-parts":[[2021,6,16]]}},"URL":"https:\/\/doi.org\/10.1210\/clinem\/dgab151","relation":{},"ISSN":["0021-972X","1945-7197"],"issn-type":[{"value":"0021-972X","type":"print"},{"value":"1945-7197","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2021,7,1]]},"published":{"date-parts":[[2021,3,8]]}}}